Clinical effect observation on acupuncture for chronic obstructive pulmonary disease
Conclusion
Seretide inhaler combined with acupuncture can improve signs and symptoms in COPD patients, increase the 6-MWT distance, improve FEV1% and obtain better results than Seretide alone. (Source: Journal of Acupuncture and Tuina Science)
Source: Journal of Acupuncture and Tuina Science - October 1, 2015 Category: Complementary Medicine Source Type: research
Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
Background:
Umeclidinium (UMEC; long-acting muscarinic antagonist) plus vilanterol (VI; long-acting beta
2
agonist [LABA]) and the LABA/inhaled corticosteroid fluticasone propionate/salmeterol (FP/SAL) are approved maintenance treatments for chronic obstructive pulmonary disease (COPD). This 12-week, multicentre, double-blind, parallel-group, double-dummy study compared the efficacy and safety of these treatments in symptomatic patients with moderate-to-severe COPD with no exacerbations in the year prior to enrolment.
Methods:
Patients (n = 717) were randomised 1:1 to once-dail...
Source: BMC Pulmonary Medicine - August 19, 2015 Category: Respiratory Medicine Authors: Dave SinghSally WorsleyChang-Qing ZhuLiz HardakerAlison Church Source Type: research
Population Pharmacokinetics οf Fluticasone Propionate / Salmeterol Using Two Different Dry Powder Inhalers.
Abstract
The combination of fluticasone propionate (FLP) and salmeterol (SAL) is often used in clinical practice for the treatment of pulmonary disorders. The purpose of this study was to explore the pharmacokinetics (PK) of inhaled FLP and SAL, after concomitant administration, in healthy male and female subjects using two dry powder inhalers. Plasma concentration (C) - time (t) data were obtained from a single dose, two-sequence, two-period, crossover (2x2) bioequivalence (BE) study. Activated charcoal was co-administered in order to prohibit absorption from the gastrointestinal tract. A number of 60 sub...
Source: European Journal of Pharmaceutical Sciences - August 18, 2015 Category: Drugs & Pharmacology Authors: Soulele K, Macheras P, Silvestro L, Rizea Savu S, Karalis V Tags: Eur J Pharm Sci Source Type: research
Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations
We read with interest the article by James F. Donohue et al, which summarized the results of two identical studies on the once-daily (od) long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination, vilanterol (VIL)/umeclidinium (UMEC) and the twice-daily (bid) LABA/inhaled corticosteroid (ICS) combination salmeterol (SAL)/fluticasone propionate (FP). The primary endpoint was least squares mean change from baseline in 0 to 24-h weighted mean FEV1 versus FP/SAL on Day 84 in patients with moderate-to-severe COPD, without a documented history of COPD exacerbation in the year before screening [1]. (Sour...
Source: Respiratory Medicine CME - July 16, 2015 Category: Respiratory Medicine Authors: Donald Banerji, Francesco Patalano Tags: Correspondence Source Type: research
Safety of Fluticasone Propionate Prescribed for Asthma During Pregnancy: A UK Population-Based Cohort Study
Conclusion No increase in the overall risk of MCMs was identified after first trimester FP exposure compared with non-FP ICS. (Source: The Journal of Allergy and Clinical Immunology: In Practice)
Source: The Journal of Allergy and Clinical Immunology: In Practice - June 26, 2015 Category: Allergy & Immunology Source Type: research
Plume Characteristics of Two HFA-Driven Inhaled Corticosteroid/Long-Acting Beta2-Agonist Combination Pressurized Metered-Dose Inhalers
Conclusion
There were substantial differences between the plumes of the two pMDIs. FP/FORM was warmer, less forceful, had a longer plume duration and slower maximal velocity. These plume characteristics of FP/FORM may lead to improved lung deposition.
Funding
Mundipharma Research Limited, Cambridge, UK. (Source: Advances in Therapy)
Source: Advances in Therapy - June 23, 2015 Category: Drugs & Pharmacology Source Type: research
Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids.
CONCLUSIONS: There is currently no evidence from randomised trials to inform the discontinuation of LABAs in children once asthma control is achieved with ICS plus LABA. It is disappointing that such an important issue has not been studied, and a randomised double-blind trial recruiting children who are controlled on ICS plus LABA is warranted. The study should be large enough to assess children of different ages, and to measure the important safety and efficacy outcomes suggested in this review over at least six months.The only randomised evidence for stopping LABA has been conducted in adults; it will be summarised in a ...
Source: Cochrane Database of Systematic Reviews - May 21, 2015 Category: Journals (General) Authors: Kew KM, Beggs S, Ahmad S Tags: Cochrane Database Syst Rev Source Type: research
Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study--a randomised controlled trial
Conclusions
GLY+SAL/FP showed comparable improvements in lung function, health status and rescue medication to TIO+SAL/FP. Importantly, addition of GLY to SAL/FP demonstrated significant improvements in lung function, health status and rescue medication compared to SAL/FP.
Trial registration number
NCT01513460. (Source: Thorax)
Source: Thorax - May 14, 2015 Category: Respiratory Medicine Authors: Frith, P. A., Thompson, P. J., Ratnavadivel, R., Chang, C. L., Bremner, P., Day, P., Frenzel, C., Kurstjens, N., the Glisten Study Group, Waddell, Daniel, Khoussousi, Springfield, Veale, Graham, Gallagher, Pande, O'Kane, Jones, Baldi, Helm, O'Dochartaigh, Tags: Clinical trials (epidemiology), Open access, Drugs: respiratory system Chronic obstructive pulmonary disease Source Type: research
Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations
Umeclidinium (UMEC; long-acting muscarinic antagonist [LAMA])/vilanterol (VI; long-acting beta2-agonist [LABA]) and fluticasone propionate/salmeterol (FP/SAL) (inhaled corticosteroid/LABA) are approved maintenance therapies for chronic obstructive pulmonary disease (COPD). Two studies compared efficacy and safety of UMEC/VI with FP/SAL in patients with moderate-to-severe COPD with no exacerbations in the previous year. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - May 7, 2015 Category: Respiratory Medicine Authors: James F. Donohue, Sally Worsley, Chang-Qing Zhu, Liz Hardaker, Alison Church Source Type: research
Medication Guide Reading Behaviors and Attitudes Among Subjects With Migraine, Asthma, or COPD
Conclusions:
The results provide insights into potential revisions to the medication guides that may improve reading behaviors. (Source: Therapeutic Innovation and Regulatory Science)
Source: Therapeutic Innovation and Regulatory Science - April 30, 2015 Category: Drugs & Pharmacology Authors: Bibeau, K. B., DiSantostefano, R. L., Hinds, D. Tags: Policy Source Type: research
Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler
Conclusions
SFC 50/100 µg Rotacaps®/Rotahaler® showed comparable fluticasone propionate and salmeterol systemic exposure to Diskus® for all pharmacokinetic endpoints with GMR and both upper and lower limits of 90 % CIs within conventional acceptance criteria for bioequivalence (0.8, 1.25), sufficient for considering progression of the Rotacaps®/Rotahaler® product for further clinical development. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - March 25, 2015 Category: Drugs & Pharmacology Source Type: research
Pharmacodynamic Studies to Demonstrate Bioequivalence of Oral Inhalation Products
Discussion focused on whether PK would be the most sensitive marker of bioequivalence. Furthermore, there was much discussion about the FDA draft guidance for generic fluticasone propionate/salmeterol. The opinion was expressed that the study design is not capable of detecting a non-equivalent product and would require an unfeasibly large sample size. (Source: The AAPS Journal)
Source: The AAPS Journal - February 26, 2015 Category: Drugs & Pharmacology Source Type: research
Fluticasone furoate/vilanterol dry-powder inhaler: a guide to its use in chronic obstructive pulmonary disease
Abstract
The fixed combination of the corticosteroid fluticasone furoate with the long-acting β2-adrenergic agonist vilanterol is an effective and generally well tolerated inhalation agent for the treatment of chronic obstructive pulmonary disease (COPD). Fluticasone furoate/vilanterol (Relvar®, Breo®, Revinty®) inhaled once daily via a dry-powder inhaler (Ellipta®) provided rapid and sustained improvements in pulmonary function, which were at least as good as those achieved with twice-daily fluticasone propionate/salmeterol and, over the long term, reduced exacerbation rates in clinical trials in pa...
Source: Drugs and Therapy Perspectives - February 19, 2015 Category: Drugs & Pharmacology Source Type: research
Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD ¿ mixed treatment comparisons of clinical efficacy
Conclusions:
FF/VI 100/25 mcg was comparable with corresponding doses of FP/SAL and BUD/FORM on lung function and health status outcomes. Non-inferiority on moderate/severe exacerbation rate was not demonstrated to the same degree of confidence, though observed rates were similar. Model limitations include a weak treatment network for the exacerbation analysis and variability across the included studies. Our data support previous RCT findings suggesting that the efficacy of FF/VI 100/25 mcg on lung function and health status in COPD is comparable with twice-daily ICS/LABAs. (Source: Respiratory Research)
Source: Respiratory Research - February 15, 2015 Category: Respiratory Medicine Authors: Gillian StynesHenrik SvedsaterJaro WexSally LettisDavid LeatherEmanuela CastelnuovoMichelle DetryScott Berry Source Type: research
Once-daily fluticasone furoate/vilanterol 100/25mcg versus twice daily combination therapies in COPD ¿ mixed treatment comparisons of clinical efficacy
Conclusions:
FF/VI 100/25mcg was comparable with corresponding doses of FP/SAL and BUD/FORM on lung function and health status outcomes. Non-inferiority on moderate/severe exacerbation rate was not demonstrated to the same degree of confidence, though observed rates were similar. Model limitations include a weak treatment network for the exacerbation analysis and variability across the included studies. Our data support previous RCT findings suggesting that the efficacy of FF/VI 100/25mcg on lung function and health status in COPD is comparable with twice-daily ICS/LABAs. (Source: Respiratory Research)
Source: Respiratory Research - February 15, 2015 Category: Respiratory Medicine Authors: Gillian StynesHenrik SvedsaterJaro WexSally LettisDavid LeatherEmanuela CastelnuovoMichelle DetryScott Berry Source Type: research
